Cargando…

Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury

Renal ischemia-reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI). Many investigators have reported that cell death via apoptosis significantly contributed to the pathophysiology of renal IRI. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Adachi, Takaomi, Sugiyama, Noriyuki, Gondai, Tatsuro, Yagita, Hideo, Yokoyama, Takahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Society of Histochemistry and Cytochemistry 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929614/
https://www.ncbi.nlm.nih.gov/pubmed/24610963
http://dx.doi.org/10.1267/ahc.13022
_version_ 1782304416844480512
author Adachi, Takaomi
Sugiyama, Noriyuki
Gondai, Tatsuro
Yagita, Hideo
Yokoyama, Takahiko
author_facet Adachi, Takaomi
Sugiyama, Noriyuki
Gondai, Tatsuro
Yagita, Hideo
Yokoyama, Takahiko
author_sort Adachi, Takaomi
collection PubMed
description Renal ischemia-reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI). Many investigators have reported that cell death via apoptosis significantly contributed to the pathophysiology of renal IRI. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily, and induces apoptosis and inflammation. However, the role of TRAIL in renal IRI is unclear. Here, we investigated whether TRAIL contributes to renal IRI and whether TRAIL blockade could attenuate renal IRI. AKI was induced by unilateral clamping of the renal pedicle for 60 min in male FVB/N mice. We found that the expression of TRAIL and its receptors were highly upregulated in renal tubular cells in renal IRI. Neutralizing anti-TRAIL antibody or its control IgG was given 24 hr before ischemia and a half-dose booster injection was administered into the peritoneal cavity immediately after reperfusion. We found that TRAIL blockade inhibited tubular apoptosis and reduced the accumulation of neutrophils and macrophages. Furthermore, TRAIL blockade attenuated renal fibrosis and atrophy after IRI. In conclusion, our study suggests that TRAIL is a critical pathogenic factor in renal IRI, and that TRAIL could be a new therapeutic target for the prevention of renal IRI.
format Online
Article
Text
id pubmed-3929614
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Japan Society of Histochemistry and Cytochemistry
record_format MEDLINE/PubMed
spelling pubmed-39296142014-04-01 Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury Adachi, Takaomi Sugiyama, Noriyuki Gondai, Tatsuro Yagita, Hideo Yokoyama, Takahiko Acta Histochem Cytochem Regular Article Renal ischemia-reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI). Many investigators have reported that cell death via apoptosis significantly contributed to the pathophysiology of renal IRI. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily, and induces apoptosis and inflammation. However, the role of TRAIL in renal IRI is unclear. Here, we investigated whether TRAIL contributes to renal IRI and whether TRAIL blockade could attenuate renal IRI. AKI was induced by unilateral clamping of the renal pedicle for 60 min in male FVB/N mice. We found that the expression of TRAIL and its receptors were highly upregulated in renal tubular cells in renal IRI. Neutralizing anti-TRAIL antibody or its control IgG was given 24 hr before ischemia and a half-dose booster injection was administered into the peritoneal cavity immediately after reperfusion. We found that TRAIL blockade inhibited tubular apoptosis and reduced the accumulation of neutrophils and macrophages. Furthermore, TRAIL blockade attenuated renal fibrosis and atrophy after IRI. In conclusion, our study suggests that TRAIL is a critical pathogenic factor in renal IRI, and that TRAIL could be a new therapeutic target for the prevention of renal IRI. Japan Society of Histochemistry and Cytochemistry 2013-12-28 2013-11-22 /pmc/articles/PMC3929614/ /pubmed/24610963 http://dx.doi.org/10.1267/ahc.13022 Text en © 2013 The Japan Society of Histochemistry and Cytochemistry This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Regular Article
Adachi, Takaomi
Sugiyama, Noriyuki
Gondai, Tatsuro
Yagita, Hideo
Yokoyama, Takahiko
Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
title Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
title_full Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
title_fullStr Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
title_full_unstemmed Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
title_short Blockade of Death Ligand TRAIL Inhibits Renal Ischemia Reperfusion Injury
title_sort blockade of death ligand trail inhibits renal ischemia reperfusion injury
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929614/
https://www.ncbi.nlm.nih.gov/pubmed/24610963
http://dx.doi.org/10.1267/ahc.13022
work_keys_str_mv AT adachitakaomi blockadeofdeathligandtrailinhibitsrenalischemiareperfusioninjury
AT sugiyamanoriyuki blockadeofdeathligandtrailinhibitsrenalischemiareperfusioninjury
AT gondaitatsuro blockadeofdeathligandtrailinhibitsrenalischemiareperfusioninjury
AT yagitahideo blockadeofdeathligandtrailinhibitsrenalischemiareperfusioninjury
AT yokoyamatakahiko blockadeofdeathligandtrailinhibitsrenalischemiareperfusioninjury